Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Rose

Showing results (81-90 of 277) with videos related to

Pageof 28
Sort By:
Public Health Reports (Washington, D.C. : 1974)|January 1, 1984
The underreporting of disease and physicians' knowledge of reporting requirementsP M Konowitz, G A Petrossian, D N Rose
JAMA|November 21, 1986
The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactorsD N Rose, C B Schechter, A L Silver
The American Journal of Medicine|February 1, 1993
Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysisD N Rose, C B Schechter, H S Sacks
Journal of General Internal Medicine|November 1, 1992
Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patientsD N Rose, C B Schechter, H S Sacks
Transfusion|July 9, 2011
An analysis of mobile whole blood collection labor efficiencyWilliam N Rose, Paula J Dayton, Thomas J Raife
Journal of General Internal Medicine|November 1, 1995
Interpretation of the tuberculin skin testD N Rose, C B Schechter, J J Adler
Schweizerische Medizinische Wochenschrift|November 30, 1996
[Tuberculosis therapy in canton Zurich 1991-1993: what are the causes for recurrence and therapy failure?]N Rose, H Shang, G E Pfyffer, et al.
The British Journal of Disorders of Communication|April 1, 1978
Classification of infant vocalizationR E Stark, S N Rose, P J Benson
The Mount Sinai Journal of Medicine, New York|April 1, 1985
Tuberculosis chemoprophylaxis for diabetics: are the benefits of isoniazid worth the risk?D N Rose, A L Silver, C B Schechter
AIDS (London, England)|August 28, 1999
Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effectiveJ C Bell, D N Rose, H S Sacks
Pageof 28

Showing results (81-90 of 277) with videos related to

Sort By:
Pageof 28
Public Health Reports (Washington, D.C. : 1974)|January 1, 1984
The underreporting of disease and physicians' knowledge of reporting requirementsP M Konowitz, G A Petrossian, D N Rose
JAMA|November 21, 1986
The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactorsD N Rose, C B Schechter, A L Silver
The American Journal of Medicine|February 1, 1993
Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysisD N Rose, C B Schechter, H S Sacks
Journal of General Internal Medicine|November 1, 1992
Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patientsD N Rose, C B Schechter, H S Sacks
Transfusion|July 9, 2011
An analysis of mobile whole blood collection labor efficiencyWilliam N Rose, Paula J Dayton, Thomas J Raife
Journal of General Internal Medicine|November 1, 1995
Interpretation of the tuberculin skin testD N Rose, C B Schechter, J J Adler
Schweizerische Medizinische Wochenschrift|November 30, 1996
[Tuberculosis therapy in canton Zurich 1991-1993: what are the causes for recurrence and therapy failure?]N Rose, H Shang, G E Pfyffer, et al.
The British Journal of Disorders of Communication|April 1, 1978
Classification of infant vocalizationR E Stark, S N Rose, P J Benson
The Mount Sinai Journal of Medicine, New York|April 1, 1985
Tuberculosis chemoprophylaxis for diabetics: are the benefits of isoniazid worth the risk?D N Rose, A L Silver, C B Schechter
AIDS (London, England)|August 28, 1999
Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effectiveJ C Bell, D N Rose, H S Sacks
Pageof 28